EPS for Allena Pharmaceuticals, Inc. (ALNA) Expected At $-0.41

July 14, 2018 - By Vernon Rice

Analysts expect Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) to report $-0.41 EPS on August, 14.After having $-0.38 EPS previously, Allena Pharmaceuticals, Inc.’s analysts see 7.89 % EPS growth. The stock decreased 2.49% or $0.29 during the last trading session, reaching $11.38. About 41,487 shares traded. Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) has 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company has market cap of $235.52 million. The company's lead product candidate includes ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It currently has negative earnings. It is also involved in developing ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases.

More news for Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) were recently published by: Streetinsider.com, which released: “Allena Pharmaceuticals, Inc.” on June 19, 2018. Globenewswire.com‘s article titled: “Allena Pharmaceuticals Completes Animal Proof-of-Concept Study for ALLN-346, Lead Product Candidate for …” and published on June 19, 2018 is yet another important article.

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.